Lumi
2D to 3D medical imaging conversion with secure cloud-based DICOM processing
Software · Cloud SaaSCompany source
Company profile
About Augmedit
Augmedit is a medical software technology company that provides augmented reality (AR) solutions for surgical guidance and visualization. Founded in 2018 in the Netherlands, the company transforms traditional 2D medical imaging into intuitive 3D holograms that surgeons can use for preoperative planning, intra-operative guidance, and patient communication. The company's mission is to provide safe, reliable, affordable and easy-to-use holographic solutions that enable better individualized treatment plans, more effective surgical collaboration, enhanced medical staff training, and improved patient engagement. Augmedit's product suite includes the Lumi cloud platform for secure DICOM image management and 3D conversion, LumiNE Lite for neurosurgical planning with automatic anatomical segmentation, and LumiNE Elite for intra-operative visualization during procedures such as External Ventricular Drain (EVD) placement. The platform is hardware-agnostic and compatible with Microsoft HoloLens 2, web, and mobile devices. The company operates on a subscription-based pricing model and serves neurosurgical staff, CMF surgeons, 3D labs, and researchers primarily in European markets, with recent FDA clearance enabling US expansion. Augmedit's vision is to become the leader in medical augmented reality applications to improve surgical outcomes and drive cost savings for healthcare institutions.
Company description Augmedit official website
Primary marketSurgical AI & Robotics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Augmedit?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Craniomaxillofacial (CMF) surgery
- External Ventricular Drain (EVD) placement
- Head and neck procedures
- Neurosurgery
Who it serves
- 3D Labs
- CMF surgery departments
- Health Systems
- Neurosurgical departments
- Research institutions
Deployment & integration
Cloud Saas · Hybrid deployment with recorded integration context.
Recorded integration context: DICOM imaging systems.
Geographic context
MarketsEuropean Union · United States
Company sourceOfficial website
Company milestones
Platform expansion
FDA Clearance for LumiNE US in 2024, closed first tranche of Series A funding in 2025, accelerating market access with Lumi and LumiNE Lite software in 2022
Partnerships
Recorded partners
- Princess Maxima Center
- UMC Utrecht
- USZ Zurich
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
LumiNE Elite
Intra-operative AR visualization for neurosurgical procedures including EVD placement
Software · HybridCompany source
LumiNE Lite
Neurosurgical planning module for automatic 3D segmentation of head anatomy
Software · Cloud SaaSCompany source
LumiNE US
FDA-cleared neurosurgical planning software for the US market
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Clinical Application and Further Development of Augmented Reality Guidance for the Surgical Localization of Pediatric Chest Wall Tumors.Journal of pediatric surgery · Aug 1, 2024
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
LumiNE US; LumiK240094 · 510k · Sep 10, 2024
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Improved patient outcomes
Through enhanced surgical visualization and planning
Cost savings
Massive cost savings for medical institutions through improved efficiency
Reduced errors
Improved visualization reduces mistakes and errors during surgery
Enhanced patient engagement
Patient-specific 3D holograms improve patient understanding and communication
UMC Utrecht
Early adoption of Augmedit's AR-based surgical planning and visualization system
University Hospital Zurich (USZ)
Implementation of Augmedit's AR surgical planning system for neurosurgical procedures
Princess Maxima Center
Research and development collaboration for AR-guided surgical applications
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
06 · Company updates
Updates from Augmedit
Recent articles published on Augmedit's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Surgical AI & Robotics
Companies developing surgical technologies enhanced by AI, including robotic surgical systems, AI-powered surgical assistance and navigation tools, autonomous surgical robotics, and surgical data and analytics platforms. Covers both the performance of surgery and the analysis of surgical outcomes and OR efficiency.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.